156 related articles for article (PubMed ID: 18665367)
1. Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers.
Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut VS; Shames DM; Wendland MF; McDonald DM; Brasch RC
Eur Radiol; 2009 Jan; 19(1):121-31. PubMed ID: 18665367
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
[TBL] [Abstract][Full Text] [Related]
3. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
[TBL] [Abstract][Full Text] [Related]
4. Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF).
Cyran CC; Sennino B; Fu Y; Rogut V; Shames DM; Chaopathomkul B; Wendland MF; McDonald DM; Brasch RC; Raatschen HJ
Eur J Radiol; 2012 May; 81(5):891-6. PubMed ID: 21889860
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
6. Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice.
Sennino B; Raatschen HJ; Wendland MF; Fu Y; You WK; Shames DM; McDonald DM; Brasch RC
Magn Reson Med; 2009 Sep; 62(3):616-25. PubMed ID: 19526501
[TBL] [Abstract][Full Text] [Related]
7. MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
Turetschek K; Preda A; Floyd E; Shames DM; Novikov V; Roberts TP; Wood JM; Fu Y; Carter WO; Brasch RC
Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):448-55. PubMed ID: 12722742
[TBL] [Abstract][Full Text] [Related]
8. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
[TBL] [Abstract][Full Text] [Related]
9. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.
Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC
Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684
[TBL] [Abstract][Full Text] [Related]
10. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report.
Brasch R; Turetschek K
Eur J Radiol; 2000 Jun; 34(3):148-55. PubMed ID: 10927157
[TBL] [Abstract][Full Text] [Related]
11. Assessing tumor angiogenesis using macromolecular MR imaging contrast media.
Brasch R; Pham C; Shames D; Roberts T; van Dijke K; van Bruggen N; Mann J; Ostrowitzki S; Melnyk O
J Magn Reson Imaging; 1997; 7(1):68-74. PubMed ID: 9039595
[TBL] [Abstract][Full Text] [Related]
12. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
[TBL] [Abstract][Full Text] [Related]
13. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
[TBL] [Abstract][Full Text] [Related]
14. In vivo monitoring of angiogenesis inhibitory treatment effects by dynamic contrast-enhanced computed tomography in a xenograft tumor model.
Raatschen HJ; Fu Y; Brasch RC; Pietsch H; Shames DM; Yeh BM
Invest Radiol; 2009 May; 44(5):265-70. PubMed ID: 19346961
[TBL] [Abstract][Full Text] [Related]
15. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging enhancement of normal tissues and tumors using macromolecular Gd-based cascade polymer contrast agents: preclinical evaluations.
Raatschen HJ; Fu Y; Shames DM; Wendland MF; Brasch RC
Invest Radiol; 2006 Dec; 41(12):860-7. PubMed ID: 17099424
[TBL] [Abstract][Full Text] [Related]
17. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors].
Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC
Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional contrast enhanced ultrasound score and dynamic contrast-enhanced magnetic resonance imaging score in evaluating breast tumor angiogenesis: correlation with biological factors.
Jia WR; Chai WM; Tang L; Wang Y; Fei XC; Han BS; Chen M
Eur J Radiol; 2014 Jul; 83(7):1098-1105. PubMed ID: 24794865
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound.
Zhou J; Zheng W; Cao L; Liu M; Han F; Li A
Acad Radiol; 2010 May; 17(5):646-51. PubMed ID: 20223684
[TBL] [Abstract][Full Text] [Related]
20. Macromolecular contrast agents for MR mammography: current status.
Daldrup-Link HE; Brasch RC
Eur Radiol; 2003 Feb; 13(2):354-65. PubMed ID: 12599002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
